Therefore, this study investigated both ASO- and CasRx-based RNA targeting technologies to specifically suppress the expression level of NAB2–STAT6 fusion transcripts, which we hypothesized would exert anti-tumor benefits for SFTs. The gene discussed is STAT6; the disease is neoplasm.